middle.news
How Is Syntara Advancing Its Pipeline Amid a $5.9M Half-Year Loss?
9:08am on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
How Is Syntara Advancing Its Pipeline Amid a $5.9M Half-Year Loss?
9:08am on Thursday 26th of February, 2026 AEDT
Key Points
Half-year loss widened to $5.9 million from $2.7 million
Lead drug amsulostat advances in myelofibrosis, myelodysplastic syndromes, and pancreatic cancer trials
Received $5.6 million Australian Government R&D tax incentive
Cash reserves at $10.5 million with liabilities reduced to $3.45 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
SYNTARA (ASX:SNT)
OPEN ARTICLE